Author: Masood, K. I.; Mahmood, S. F.; Shahid, S.; Nasir, N.; Ghanchi, N.; Nasir, A.; Jamil, B.; Khanum, I.; Razzak, S.; Kanji, A.; Hasan, Z.
Title: Transcriptomic profiling of disease severity in patients with COVID-19 reveals role of blood clotting and vasculature related genes Cord-id: yrelcfx9 Document date: 2020_6_22
ID: yrelcfx9
Snippet: COVID-19 caused by SARS-CoV-2 manifests as a range of symptoms. Understanding the molecular mechanisms responsible for immuno-pathogenesis of disease is important for treatment and management of COVID-19. We examined host transcriptomes in moderate and severe COVID-19 cases with a view to identifying pathways that affect its progression. RNA extracted from whole blood of COVID-19 cases was analysed by microarray analysis. Moderate and severe cases were compared with healthy controls and differen
Document: COVID-19 caused by SARS-CoV-2 manifests as a range of symptoms. Understanding the molecular mechanisms responsible for immuno-pathogenesis of disease is important for treatment and management of COVID-19. We examined host transcriptomes in moderate and severe COVID-19 cases with a view to identifying pathways that affect its progression. RNA extracted from whole blood of COVID-19 cases was analysed by microarray analysis. Moderate and severe cases were compared with healthy controls and differentially regulated genes (DEGs) categorized into cellular pathways. DEGs in COVID-19 cases were mostly related to host immune activation and cytokine signaling, pathogen uptake, host defenses, blood and vasculature genes, and SARS-CoV-2- and other virus- affected pathways. The DEGs in these pathways were increased in severe compared with moderate cases. In a severe COVID-19 patient with an unfavourable outcome we observed dysregulation of genes in platelet homeostasis and cardiac conduction and fibrin clotting with disease progression.
Search related documents:
Co phrase search for related documents- activation pathway and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- activation pathway and acute ards respiratory distress syndrome development: 1, 2, 3
- activation pathway and acute kidney injury: 1, 2, 3
- activation pathway and acute lung: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- activation pathway and acute myocarditis: 1
- activation pathway and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- activation pathway and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- activation pathway and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9
- activation pathway and adaptive immunity: 1, 2, 3, 4
- activation pathway and lung damage: 1, 2, 3, 4, 5, 6, 7
- activation pathway and lung edema: 1
- activation pathway and lung function: 1, 2, 3, 4, 5, 6
- activation pathway and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- activation pathway and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- activation pathway and lymphocyte activation: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and adaptive immune cell: 1, 2
- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and admission hypoxic: 1
Co phrase search for related documents, hyperlinks ordered by date